In this study, we present a novel highly selective EZH2 inhibitor SHR2554, which specifically inhibits both wild-type and mutant EZH2 methyltransferase activity with similar potencies and is currently undergoing clinical trials for the treatment of lymphoma patients (NCT03603951). Here, EZH2 is linked to lymphoma.